The CNS-penetrant EGFR inhibitor, ERAS-801, shows promising nonclinical activity in a CNS metastases model of EGFR mutant NSCLC. (October 2022) - Tsang, J.; Zhao, E.; Plawat, R.; Cloughesy, T.; Nathanson, D.